NMO-IgG and Devic's neuromyelitis optica: a French experience
Background A serum autoantibody biomarker, NMO-IgG has been recently described in patients with Devic's neuromyelitis optica (DNMO) and so called `high-risk' patients for this disease. Our objectives were to replicate the test and to assess its usefulness. Methods Indirect immunofluorescen...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2008-05, Vol.14 (4), p.440-445 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 445 |
|---|---|
| container_issue | 4 |
| container_start_page | 440 |
| container_title | Multiple sclerosis |
| container_volume | 14 |
| creator | Marignier, Romain De Sèze, Jérôme Vukusic, Sandra Durand-Dubief, Françoise Zéphir, Hélène Vermersch, Patrick Cabre, Philippe Cavillon, Gaëlle Honnorat, Jérôme Confavreux, Christian |
| description | Background
A serum autoantibody biomarker, NMO-IgG has been recently described in patients with Devic's neuromyelitis optica (DNMO) and so called `high-risk' patients for this disease. Our objectives were to replicate the test and to assess its usefulness.
Methods
Indirect immunofluorescence with a substrate of adult rat cerebellum and midbrain was used to identify the distinctive NMO-IgG staining pattern. We tested masked sera from 26 patients with DNMO (group 1), 21 patients with idiopathic acute transverse myelitis (ATM) (group 2), 21 patients with bilateral and/or recurrent idiopathic optic neuritis (group 3), 52 patients with classical multiple sclerosis (MS) (group 4), 36 patients with HTLV-1 infection (group 5) and 7 patients with miscellaneous disorders (group 6).
Results
We identified a vascular staining pattern typical of NMO-IgG. This particular staining was observed in 14/26 samples in group 1, 7/21 in group 2 (positive only in longitudinally extensive acute transverse myelitis: 7/13), 4/21 in group 3 (with bilateral loss of vision in all seropositive cases), 5/52 in group 4 (none of them suggestive of DNMO), 0/36 in group 5 and 0/7 in group 6. Sensitivity of the test was 54% considering detection of DNMO (group 1), and specificity was respectively 94% and 90% when considering groups 4, 5 and 6 altogether or group 4 of MS patients only.
Conclusion
Detection of NMO-IgG is contributory to the distinction of DNMO and `DNMO high-risk' syndromes from MS. This test may allow earlier diagnosis and help therapeutic decisions. Multiple Sclerosis 2008; 14: 440—445. http://msj.sagepub.com |
| doi_str_mv | 10.1177/1352458507084595 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69441777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458507084595</sage_id><sourcerecordid>19486299</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-e9cce9ce81dbc2f1dae669a0e0128cb1d24e9ca23e5c0878510a870bdc01a6473</originalsourceid><addsrcrecordid>eNqFkU1LAzEQhoMotlbvnmTxoKfVSTa7SQQPUm0tVHvR85LNTuuW_ajJrth_b0oLQkE8DDPwPvMOM0PIOYUbSoW4pVHMeCxjECB5rOID0qdciBCUgENfeznc6D1y4twSAISI4mPSo5KBlIr1yf3ryyycLMaBrvPgEb8Kc-2CGjvbVGssi7ZwQbNqC6PvAh2MLNbmI8DvFdrCl3hKjua6dHi2ywPyPnp6Gz6H09l4MnyYhiaSqg1RGeMDJc0zw-Y015gkSgMCZdJkNGfcy5pFGBuQQsYUtBSQ5QaoTriIBuRq67uyzWeHrk2rwhksS11j07k0UZz7e_wPUsVlwpTy4OUeuGw6W_slUkaljEAC9xBsIWMb5yzO05UtKm3XKYV084B0_wG-5WLn22UV5r8Nu4t7INwCTi_wd-ifhj_8B4sZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218830804</pqid></control><display><type>article</type><title>NMO-IgG and Devic's neuromyelitis optica: a French experience</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Marignier, Romain ; De Sèze, Jérôme ; Vukusic, Sandra ; Durand-Dubief, Françoise ; Zéphir, Hélène ; Vermersch, Patrick ; Cabre, Philippe ; Cavillon, Gaëlle ; Honnorat, Jérôme ; Confavreux, Christian</creator><creatorcontrib>Marignier, Romain ; De Sèze, Jérôme ; Vukusic, Sandra ; Durand-Dubief, Françoise ; Zéphir, Hélène ; Vermersch, Patrick ; Cabre, Philippe ; Cavillon, Gaëlle ; Honnorat, Jérôme ; Confavreux, Christian</creatorcontrib><description>Background
A serum autoantibody biomarker, NMO-IgG has been recently described in patients with Devic's neuromyelitis optica (DNMO) and so called `high-risk' patients for this disease. Our objectives were to replicate the test and to assess its usefulness.
Methods
Indirect immunofluorescence with a substrate of adult rat cerebellum and midbrain was used to identify the distinctive NMO-IgG staining pattern. We tested masked sera from 26 patients with DNMO (group 1), 21 patients with idiopathic acute transverse myelitis (ATM) (group 2), 21 patients with bilateral and/or recurrent idiopathic optic neuritis (group 3), 52 patients with classical multiple sclerosis (MS) (group 4), 36 patients with HTLV-1 infection (group 5) and 7 patients with miscellaneous disorders (group 6).
Results
We identified a vascular staining pattern typical of NMO-IgG. This particular staining was observed in 14/26 samples in group 1, 7/21 in group 2 (positive only in longitudinally extensive acute transverse myelitis: 7/13), 4/21 in group 3 (with bilateral loss of vision in all seropositive cases), 5/52 in group 4 (none of them suggestive of DNMO), 0/36 in group 5 and 0/7 in group 6. Sensitivity of the test was 54% considering detection of DNMO (group 1), and specificity was respectively 94% and 90% when considering groups 4, 5 and 6 altogether or group 4 of MS patients only.
Conclusion
Detection of NMO-IgG is contributory to the distinction of DNMO and `DNMO high-risk' syndromes from MS. This test may allow earlier diagnosis and help therapeutic decisions. Multiple Sclerosis 2008; 14: 440—445. http://msj.sagepub.com</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458507084595</identifier><identifier>PMID: 18208892</identifier><identifier>CODEN: MUSCFZ</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adolescent ; Adult ; Animals ; Antibody Specificity ; Autoantibodies - blood ; Biomarkers - blood ; Child ; Cohort Studies ; Female ; Fluorescent Antibody Technique, Indirect ; France - epidemiology ; Human T-lymphotropic virus 1 ; Humans ; Immunoglobulin G - blood ; Male ; Middle Aged ; Multiple Sclerosis - epidemiology ; Multiple Sclerosis - immunology ; Myelitis, Transverse - epidemiology ; Myelitis, Transverse - immunology ; Neuromyelitis Optica - epidemiology ; Neuromyelitis Optica - immunology ; Rats ; Risk Factors ; Sensitivity and Specificity ; Seroepidemiologic Studies</subject><ispartof>Multiple sclerosis, 2008-05, Vol.14 (4), p.440-445</ispartof><rights>SAGE Publications © May 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-e9cce9ce81dbc2f1dae669a0e0128cb1d24e9ca23e5c0878510a870bdc01a6473</citedby><cites>FETCH-LOGICAL-c389t-e9cce9ce81dbc2f1dae669a0e0128cb1d24e9ca23e5c0878510a870bdc01a6473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458507084595$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458507084595$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18208892$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marignier, Romain</creatorcontrib><creatorcontrib>De Sèze, Jérôme</creatorcontrib><creatorcontrib>Vukusic, Sandra</creatorcontrib><creatorcontrib>Durand-Dubief, Françoise</creatorcontrib><creatorcontrib>Zéphir, Hélène</creatorcontrib><creatorcontrib>Vermersch, Patrick</creatorcontrib><creatorcontrib>Cabre, Philippe</creatorcontrib><creatorcontrib>Cavillon, Gaëlle</creatorcontrib><creatorcontrib>Honnorat, Jérôme</creatorcontrib><creatorcontrib>Confavreux, Christian</creatorcontrib><title>NMO-IgG and Devic's neuromyelitis optica: a French experience</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Background
A serum autoantibody biomarker, NMO-IgG has been recently described in patients with Devic's neuromyelitis optica (DNMO) and so called `high-risk' patients for this disease. Our objectives were to replicate the test and to assess its usefulness.
Methods
Indirect immunofluorescence with a substrate of adult rat cerebellum and midbrain was used to identify the distinctive NMO-IgG staining pattern. We tested masked sera from 26 patients with DNMO (group 1), 21 patients with idiopathic acute transverse myelitis (ATM) (group 2), 21 patients with bilateral and/or recurrent idiopathic optic neuritis (group 3), 52 patients with classical multiple sclerosis (MS) (group 4), 36 patients with HTLV-1 infection (group 5) and 7 patients with miscellaneous disorders (group 6).
Results
We identified a vascular staining pattern typical of NMO-IgG. This particular staining was observed in 14/26 samples in group 1, 7/21 in group 2 (positive only in longitudinally extensive acute transverse myelitis: 7/13), 4/21 in group 3 (with bilateral loss of vision in all seropositive cases), 5/52 in group 4 (none of them suggestive of DNMO), 0/36 in group 5 and 0/7 in group 6. Sensitivity of the test was 54% considering detection of DNMO (group 1), and specificity was respectively 94% and 90% when considering groups 4, 5 and 6 altogether or group 4 of MS patients only.
Conclusion
Detection of NMO-IgG is contributory to the distinction of DNMO and `DNMO high-risk' syndromes from MS. This test may allow earlier diagnosis and help therapeutic decisions. Multiple Sclerosis 2008; 14: 440—445. http://msj.sagepub.com</description><subject>Adolescent</subject><subject>Adult</subject><subject>Animals</subject><subject>Antibody Specificity</subject><subject>Autoantibodies - blood</subject><subject>Biomarkers - blood</subject><subject>Child</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Fluorescent Antibody Technique, Indirect</subject><subject>France - epidemiology</subject><subject>Human T-lymphotropic virus 1</subject><subject>Humans</subject><subject>Immunoglobulin G - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Multiple Sclerosis - immunology</subject><subject>Myelitis, Transverse - epidemiology</subject><subject>Myelitis, Transverse - immunology</subject><subject>Neuromyelitis Optica - epidemiology</subject><subject>Neuromyelitis Optica - immunology</subject><subject>Rats</subject><subject>Risk Factors</subject><subject>Sensitivity and Specificity</subject><subject>Seroepidemiologic Studies</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkU1LAzEQhoMotlbvnmTxoKfVSTa7SQQPUm0tVHvR85LNTuuW_ajJrth_b0oLQkE8DDPwPvMOM0PIOYUbSoW4pVHMeCxjECB5rOID0qdciBCUgENfeznc6D1y4twSAISI4mPSo5KBlIr1yf3ryyycLMaBrvPgEb8Kc-2CGjvbVGssi7ZwQbNqC6PvAh2MLNbmI8DvFdrCl3hKjua6dHi2ywPyPnp6Gz6H09l4MnyYhiaSqg1RGeMDJc0zw-Y015gkSgMCZdJkNGfcy5pFGBuQQsYUtBSQ5QaoTriIBuRq67uyzWeHrk2rwhksS11j07k0UZz7e_wPUsVlwpTy4OUeuGw6W_slUkaljEAC9xBsIWMb5yzO05UtKm3XKYV084B0_wG-5WLn22UV5r8Nu4t7INwCTi_wd-ifhj_8B4sZ</recordid><startdate>20080501</startdate><enddate>20080501</enddate><creator>Marignier, Romain</creator><creator>De Sèze, Jérôme</creator><creator>Vukusic, Sandra</creator><creator>Durand-Dubief, Françoise</creator><creator>Zéphir, Hélène</creator><creator>Vermersch, Patrick</creator><creator>Cabre, Philippe</creator><creator>Cavillon, Gaëlle</creator><creator>Honnorat, Jérôme</creator><creator>Confavreux, Christian</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20080501</creationdate><title>NMO-IgG and Devic's neuromyelitis optica: a French experience</title><author>Marignier, Romain ; De Sèze, Jérôme ; Vukusic, Sandra ; Durand-Dubief, Françoise ; Zéphir, Hélène ; Vermersch, Patrick ; Cabre, Philippe ; Cavillon, Gaëlle ; Honnorat, Jérôme ; Confavreux, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-e9cce9ce81dbc2f1dae669a0e0128cb1d24e9ca23e5c0878510a870bdc01a6473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Animals</topic><topic>Antibody Specificity</topic><topic>Autoantibodies - blood</topic><topic>Biomarkers - blood</topic><topic>Child</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Fluorescent Antibody Technique, Indirect</topic><topic>France - epidemiology</topic><topic>Human T-lymphotropic virus 1</topic><topic>Humans</topic><topic>Immunoglobulin G - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Multiple Sclerosis - immunology</topic><topic>Myelitis, Transverse - epidemiology</topic><topic>Myelitis, Transverse - immunology</topic><topic>Neuromyelitis Optica - epidemiology</topic><topic>Neuromyelitis Optica - immunology</topic><topic>Rats</topic><topic>Risk Factors</topic><topic>Sensitivity and Specificity</topic><topic>Seroepidemiologic Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marignier, Romain</creatorcontrib><creatorcontrib>De Sèze, Jérôme</creatorcontrib><creatorcontrib>Vukusic, Sandra</creatorcontrib><creatorcontrib>Durand-Dubief, Françoise</creatorcontrib><creatorcontrib>Zéphir, Hélène</creatorcontrib><creatorcontrib>Vermersch, Patrick</creatorcontrib><creatorcontrib>Cabre, Philippe</creatorcontrib><creatorcontrib>Cavillon, Gaëlle</creatorcontrib><creatorcontrib>Honnorat, Jérôme</creatorcontrib><creatorcontrib>Confavreux, Christian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marignier, Romain</au><au>De Sèze, Jérôme</au><au>Vukusic, Sandra</au><au>Durand-Dubief, Françoise</au><au>Zéphir, Hélène</au><au>Vermersch, Patrick</au><au>Cabre, Philippe</au><au>Cavillon, Gaëlle</au><au>Honnorat, Jérôme</au><au>Confavreux, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NMO-IgG and Devic's neuromyelitis optica: a French experience</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2008-05-01</date><risdate>2008</risdate><volume>14</volume><issue>4</issue><spage>440</spage><epage>445</epage><pages>440-445</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><coden>MUSCFZ</coden><abstract>Background
A serum autoantibody biomarker, NMO-IgG has been recently described in patients with Devic's neuromyelitis optica (DNMO) and so called `high-risk' patients for this disease. Our objectives were to replicate the test and to assess its usefulness.
Methods
Indirect immunofluorescence with a substrate of adult rat cerebellum and midbrain was used to identify the distinctive NMO-IgG staining pattern. We tested masked sera from 26 patients with DNMO (group 1), 21 patients with idiopathic acute transverse myelitis (ATM) (group 2), 21 patients with bilateral and/or recurrent idiopathic optic neuritis (group 3), 52 patients with classical multiple sclerosis (MS) (group 4), 36 patients with HTLV-1 infection (group 5) and 7 patients with miscellaneous disorders (group 6).
Results
We identified a vascular staining pattern typical of NMO-IgG. This particular staining was observed in 14/26 samples in group 1, 7/21 in group 2 (positive only in longitudinally extensive acute transverse myelitis: 7/13), 4/21 in group 3 (with bilateral loss of vision in all seropositive cases), 5/52 in group 4 (none of them suggestive of DNMO), 0/36 in group 5 and 0/7 in group 6. Sensitivity of the test was 54% considering detection of DNMO (group 1), and specificity was respectively 94% and 90% when considering groups 4, 5 and 6 altogether or group 4 of MS patients only.
Conclusion
Detection of NMO-IgG is contributory to the distinction of DNMO and `DNMO high-risk' syndromes from MS. This test may allow earlier diagnosis and help therapeutic decisions. Multiple Sclerosis 2008; 14: 440—445. http://msj.sagepub.com</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>18208892</pmid><doi>10.1177/1352458507084595</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2008-05, Vol.14 (4), p.440-445 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69441777 |
| source | SAGE Complete A-Z List; MEDLINE |
| subjects | Adolescent Adult Animals Antibody Specificity Autoantibodies - blood Biomarkers - blood Child Cohort Studies Female Fluorescent Antibody Technique, Indirect France - epidemiology Human T-lymphotropic virus 1 Humans Immunoglobulin G - blood Male Middle Aged Multiple Sclerosis - epidemiology Multiple Sclerosis - immunology Myelitis, Transverse - epidemiology Myelitis, Transverse - immunology Neuromyelitis Optica - epidemiology Neuromyelitis Optica - immunology Rats Risk Factors Sensitivity and Specificity Seroepidemiologic Studies |
| title | NMO-IgG and Devic's neuromyelitis optica: a French experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A59%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NMO-IgG%20and%20Devic's%20neuromyelitis%20optica:%20a%20French%20experience&rft.jtitle=Multiple%20sclerosis&rft.au=Marignier,%20Romain&rft.date=2008-05-01&rft.volume=14&rft.issue=4&rft.spage=440&rft.epage=445&rft.pages=440-445&rft.issn=1352-4585&rft.eissn=1477-0970&rft.coden=MUSCFZ&rft_id=info:doi/10.1177/1352458507084595&rft_dat=%3Cproquest_cross%3E19486299%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218830804&rft_id=info:pmid/18208892&rft_sage_id=10.1177_1352458507084595&rfr_iscdi=true |